Acute Myeloid Leukemia in Children: Standard of Care and Future Perspectives

About

Dr. Daisuke Tomizawa is a pediatric hematologist/oncologist and Head of the Division of Leukemia and Lymphoma at the Children's Cancer Center National Center for Child Health and Development in Tokyo Japan. He served as Vice Chair of the Japan Children's Cancer Group (JCCG) acute myeloid leukemia (AML) disease committee from 2010-2019 and Chair from 2019-2023 which is responsible for the design and conduct of clinical trials and linked translational research studies that enroll approximately 80% of Japanese children and adolescents with this disease. He is also involved in various international research projects in collaboration with North American Western European and Asian investigators in this field. Dr. Edward Anders Kolb is a pediatric hematologist/oncologist and most recently served as Chief of the Division of Hematology and Oncology of Nemours Childrens Health Wilmington Delaware and Professor of Pediatrics Sidney Kimmel Medical College at Thomas Jefferson University. Dr. Kolb also served as Chair of the Childrens Oncology Group (COG) Myeloid Disease Committee from 2013-2023 which is the largest pediatric AML research consortium in the world. He is a strong advocate for international collaboration and leads the development of several international clinical trials. Since 2023 Dr. Kolb was appointed as President and Chief Executive Officer The Leukemia & Lymphoma Society (LLS) in its mission to cure blood cancers and improve the quality of life for patients and their families. Prof. Dr. Dirk Reinhardt is a pediatric hematologist/oncologist and Head of Pediatrics III Pediatric Hematology Oncology and Stem Cell Therapy at the University Children's Hospital Essen Germany. He is chairman of the AML-BFM study group which conducts clinical trials as well as basic and translational research on pediatric AML. As Managing Director of the German Society for Pediatric Oncology and Hematology (GPOH gGmbH) and Director of the EuPAL Foundation he promotes international projects in drug and therapy development for the treatment of cancer and leukemia in children.